Phase II BGG492 Capsule Extension for Partial Epilepsy
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT01338805
- Locations
- 🇸🇰
Novartis Investigative Site, Kosice, Slovakia
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
- Conditions
- Multiple MyelomaRenal Insufficiency
- Interventions
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01337752
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
🇺🇸University Chicago Hospital Dept. of Univ of Chicago (2), Chicago, Illinois, United States
🇺🇸Medical Oncology Associates, PS, Spokane, Washington, United States
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT01336634
- Locations
- 🇬🇧
Novartis Investigative Site, Sutton, United Kingdom
Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT01335035
- Locations
- 🇪🇸
Novartis Investigative Site, Murcia, Spain
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT01333501
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Safety and Efficacy of LCI699 in Cushing's Disease Patients
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01331239
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇯🇵Novartis Investigative Site, Chiba, Japan
🇺🇸Massachusetts General Hospital Neuroendocrine Unit, Boston, Massachusetts, United States
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT01328886
- Locations
- 🇯🇵
Novartis Investigative Site, Gifu, Japan
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
- Conditions
- Atherosclerosis
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10066
- Registration Number
- NCT01327846
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
- Conditions
- Uveitis
- Interventions
- Biological: AIN457
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01327664
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT01327053
- Locations
- 🇺🇸
Washington Hospital Center Wash Hospital, Washington, District of Columbia, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2), Las Vegas, Nevada, United States